SCHEMBL2276169

SCHEMBL2276169

Nc1ccc(C(=O)Nc2cc(Oc3ccccc3)ccc2C(=O)O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 1/20 0.60
HPSE Q9Y251 1/20 0.56
NR1H4 Q96RI1 2/20 0.54
TDP1 Q9NUW8 2/20 0.54
GALK1 P51570 1/20 0.54
CASP6 P55212 1/20 0.54
MCL1 Q07820 1/20 0.54
PLEC Q15149 1/20 0.54
PYGL P06737 1/20 0.53
PYGM P11217 1/20 0.53
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
PKM P14618 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
MAPT P10636 1/20 0.51
GRIK1 P39086 1/20 0.51
HDAC1 Q13547 2/20 0.51
HDAC8 Q9BY41 2/20 0.51
HDAC6 Q9UBN7 2/20 0.51
HDAC3 O15379 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2271588 0.91 SERPINE1 (0.64) SERPINE1HPSENR1H4TDP1GALK1
SCHEMBL2270621 0.88 GALK1 (0.68) SERPINE1HPSENR1H4TDP1GALK1
SCHEMBL2276745 0.88 SERPINE1 (0.65) SERPINE1HPSENR1H4TDP1GALK1
SCHEMBL2272043 0.87 SERPINE1 (0.75) SERPINE1HPSENR1H4TDP1GALK1
SCHEMBL2273634 0.87 SERPINE1 (0.60) SERPINE1HPSENR1H4TDP1GALK1
SCHEMBL2275467 0.87 CYP2C9 (0.63) SERPINE1HPSENR1H4TDP1GALK1
SCHEMBL2271007 0.87 MEN1 (0.69) SERPINE1HPSENR1H4PYGMMEN1
SCHEMBL2272774 0.85 KMT2A (0.63) SERPINE1HPSENR1H4TDP1GALK1
SCHEMBL2275706 0.85 SERPINE1 (0.58) SERPINE1HPSENR1H4TDP1GALK1
SCHEMBL2274217 0.85 CYP2C9 (0.57) SERPINE1HPSENR1H4TDP1PYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 SERPINE1 101/4885HPSE 1324/4885NR1H4 2482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.